Logo image of GDTC

CYTOMED THERAPEUTICS LTD (GDTC) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:GDTC - SGXZ17669631 - Common Stock

1.77 USD
-0.08 (-4.32%)
Last: 12/5/2025, 8:24:14 PM
1.77 USD
0 (0%)
After Hours: 12/5/2025, 8:24:14 PM
Fundamental Rating

2

GDTC gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. While GDTC seems to be doing ok healthwise, there are quite some concerns on its profitability. GDTC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year GDTC has reported negative net income.
GDTC had a negative operating cash flow in the past year.
GDTC had negative earnings in each of the past 5 years.
GDTC had a negative operating cash flow in each of the past 5 years.
GDTC Yearly Net Income VS EBIT VS OCF VS FCFGDTC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -1M -2M -3M -4M

1.2 Ratios

GDTC has a Return On Assets (-43.94%) which is comparable to the rest of the industry.
The Return On Equity of GDTC (-51.38%) is better than 65.23% of its industry peers.
Industry RankSector Rank
ROA -43.94%
ROE -51.38%
ROIC N/A
ROA(3y)-39.42%
ROA(5y)-40.55%
ROE(3y)-198.44%
ROE(5y)-215.73%
ROIC(3y)N/A
ROIC(5y)N/A
GDTC Yearly ROA, ROE, ROICGDTC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

GDTC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GDTC Yearly Profit, Operating, Gross MarginsGDTC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -1K -2K -3K

More info and screens

5

2. Health

2.1 Basic Checks

GDTC does not have a ROIC to compare to the WACC, probably because it is not profitable.
GDTC has about the same amout of shares outstanding than it did 1 year ago.
GDTC has more shares outstanding than it did 5 years ago.
The debt/assets ratio for GDTC is higher compared to a year ago.
GDTC Yearly Shares OutstandingGDTC Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
GDTC Yearly Total Debt VS Total AssetsGDTC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

GDTC has an Altman-Z score of 9.84. This indicates that GDTC is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 9.84, GDTC belongs to the top of the industry, outperforming 81.50% of the companies in the same industry.
A Debt/Equity ratio of 0.06 indicates that GDTC is not too dependend on debt financing.
GDTC's Debt to Equity ratio of 0.06 is on the low side compared to the rest of the industry. GDTC is outperformed by 61.31% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z 9.84
ROIC/WACCN/A
WACC8.67%
GDTC Yearly LT Debt VS Equity VS FCFGDTC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 5M 10M

2.3 Liquidity

A Current Ratio of 5.81 indicates that GDTC has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.81, GDTC is in the better half of the industry, outperforming 60.56% of the companies in the same industry.
A Quick Ratio of 5.81 indicates that GDTC has no problem at all paying its short term obligations.
GDTC has a Quick ratio of 5.81. This is in the better half of the industry: GDTC outperforms 61.87% of its industry peers.
Industry RankSector Rank
Current Ratio 5.81
Quick Ratio 5.81
GDTC Yearly Current Assets VS Current LiabilitesGDTC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

0

3. Growth

3.1 Past

GDTC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -19.89%.
EPS 1Y (TTM)-19.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-106.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-13.33%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-8.93%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GDTC Yearly Revenue VS EstimatesGDTC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 100K 200K 300K 400K 500K
GDTC Yearly EPS VS EstimatesGDTC Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 -0.05 -0.1 -0.15 -0.2 -0.25

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GDTC. In the last year negative earnings were reported.
Also next year GDTC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GDTC Price Earnings VS Forward Price EarningsGDTC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GDTC Per share dataGDTC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GDTC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CYTOMED THERAPEUTICS LTD

NASDAQ:GDTC (12/5/2025, 8:24:14 PM)

After market: 1.77 0 (0%)

1.77

-0.08 (-4.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2025-11-14
Earnings (Next)04-28 2026-04-28
Inst Owners0.2%
Inst Owner ChangeN/A
Ins Owners12.62%
Ins Owner Change0%
Market Cap20.66M
Revenue(TTM)225.40K
Net Income(TTM)-3.67M
Analysts82.86
Price Target5.1 (188.14%)
Short Float %0.58%
Short Ratio0.16
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 118.7
P/FCF N/A
P/OCF N/A
P/B 3.74
P/tB 3.78
EV/EBITDA N/A
EPS(TTM)-0.25
EYN/A
EPS(NY)-0.13
Fwd EYN/A
FCF(TTM)-0.27
FCFYN/A
OCF(TTM)-0.21
OCFYN/A
SpS0.01
BVpS0.47
TBVpS0.47
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -43.94%
ROE -51.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.42%
ROA(5y)-40.55%
ROE(3y)-198.44%
ROE(5y)-215.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 267.85%
Cap/Sales 413.53%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.81
Quick Ratio 5.81
Altman-Z 9.84
F-Score3
WACC8.67%
ROIC/WACCN/A
Cap/Depr(3y)193.79%
Cap/Depr(5y)170.05%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-106.15%
EPS Next Y-13.33%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-8.93%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y18.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-35.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-6.75%
OCF growth 3YN/A
OCF growth 5YN/A

CYTOMED THERAPEUTICS LTD / GDTC FAQ

Can you provide the ChartMill fundamental rating for CYTOMED THERAPEUTICS LTD?

ChartMill assigns a fundamental rating of 2 / 10 to GDTC.


What is the valuation status of CYTOMED THERAPEUTICS LTD (GDTC) stock?

ChartMill assigns a valuation rating of 0 / 10 to CYTOMED THERAPEUTICS LTD (GDTC). This can be considered as Overvalued.


Can you provide the profitability details for CYTOMED THERAPEUTICS LTD?

CYTOMED THERAPEUTICS LTD (GDTC) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for GDTC stock?

The Earnings per Share (EPS) of CYTOMED THERAPEUTICS LTD (GDTC) is expected to decline by -13.33% in the next year.